CD44 isoform expression in synovial sarcoma correlates with epitheliogenesis but not prognosis

Histopathology

Volumn 37, Issue 2, 2000, Pages 166-174

  Sneath, R J ^a   Mangham, D C ^a  

^a ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

CD44; Differentiation; Epithelial; Immunohistochemical; Prognosis; Sarcoma; Synovial

Indexed keywords

CD44V ANTIGEN; EPITOPE; HERMES ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SYNOVIAL SARCOMA;

ANTIGENS, CD44; CELL DIFFERENTIATION; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTEIN ISOFORMS; SARCOMA, SYNOVIAL;

EID: 0033852941     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.00953.x     Document Type: Article

References (65)

1. Idzerda R, Carter W, Nottenburg C, Wayner E, Gallatin W, St John T. Isolation and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium. Proc. Natl Acad. Sci. USA 1989; 86; 4659-4663.
2. Goodfellow PN, Banting G, Wiles MV et al. The gene. MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2 is on human chromosome 11. Eur. J. Immunol. 1982; 12; 659-663.
3. Aruffo A, Stamenkovic I, Melnick M, Underhill C, Seed B. CD44 is the principle cell surface receptor for hyaluronate. Cell 1990; 61; 1303-1313.
4. Wayer E, Carter W. Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits. J. Cell Biol. 1987; 105; 1873-1884.
5. Lesley J, Schulte R, Hyman R. Binding of hyaluronic acid to lymphoid cell lines is inhibited by monoclonal antibodies against Pgp-1. Exp. Cell Res. 1990; 187; 224-233.
6. Lesley J, He Q, Miyake K, Hamann A, Hyman R, Kincade P. Requirements for hyaluronic acid binding by CD44: a role for the cytoplasmic domain and activation by antibody. J. Exp. Med. 1992; 175; 257-266.
7. Underhill C, Toole B. Physical characteristics of hyaluronate binding to the surface of simian virus 40 transformed 3T3 cells. J. Biol. Chem. 1980; 255; 4544-4549.
8. Lesley J, Kincade P, Hyman R. Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding of antibody. Eur. J. Immunol. 1993; 23; 1902-1909.
9. Shimizu Y, Seventer van G, Siraganian R, Wahl L, Shaw S. Dual role of the CD44 molecule in T-cell adhesion and activation. J. Immunol. 1989; 143; 2457-2463.
10. Huet S, Groux H, Caillou B, Valentin H, Prieur A, Bernard A. CD44 contributes to t-cell activation. J. Immunol. 1989; 143; 798-801.
11. Conrad P, Rothman B, Kelley K, Blue M. Mechanism of peripheral T cell activation by coengagement of CD44 and CD2. J. Immunol. 1992; 149; 1833-1839.
12. Arch. R, Wirth K, Hofmann M, Ponta H et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992; 257; 682-685.
13. Koopman G, Heider K-H, Horst E et al. Activated human lymphocytes and aggressive non-Hodgkin lymphomas express a homologue of the rat metastasis-associated variant of CD44. J. Exp. Med. 1993; 177; 897-904.
14. Jalkanen S, Bargatze R, Herron L, Butcher E. A lymphoid cell surface glycoprotien involved in endothelial cell recognition and lymphocyte homing in man. Eur. J. Immunol. 1986; 16; 1195-1202.
15. Jalkanen S, Bargatze R, DeLosToyes J, Butcher E. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95 kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J. Cell Biol. 1987; 105; 983-990.
16. Gunthert U, Hofmann M, Rudy W et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65; 13-24.
17. Guo Y, Ma J, Wang J et al. Inhibition of human melanoma growth and metastsis in vivo by anti-CD44 monoclonal antibody. Cancer Res. 1994; 54; 1561-1565.
18. Hofmann M, Rudy W, Günthert U et al. A link between ras and metastatic behaviour of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastases-specific variants of CD44 in CREF cells. Cancer Res. 1993; 53; 1516-1521.
19. Stamenkovic I, Amiot M, Pesando J, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989; 56; 1057-1062.
20. Horst E, Meijer C, Radaszkiewicz T, Ossekoppele G, Van Krieken J, Pals S. Adhesion molecules in the prognosis of diffuse large-cell lymphoma: expression of a lymphocyte homing receptor (CD44), LFA-1 (CD11a/18), and ICAM-1 (CD54). Leukemia 1990; 4; 595-599.
21. Zigmund S. Cell locomotion and chemotaxis. Curr. Opin. Cell Biol. 1989; 1; 80-86.
22. Namec R, Toole B, Knudson T. The cell surface hyaluronate binding sites of invasive human bladder carcinoma cells. Biochem. Biophys. Res. Commun. 1987; 149; 249-257.
23. Hudson D, Speight P, Watt F. Altered expression of CD44 isoforms in squamous-cell carcinomas and cell lines derived from them. Int. J. Cancer 1996; 66; 457-463.
24. Salmi M, Grön-Virta K, Sointu P, Grenman R, Kalimo H, Jalkanen S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J. Cell Biol. 1993; 122; 431-442
25. Favrot M, Combaret V, Lasset C, Bérard C. CD44 - a new prognostic marker for neuroblastoma. N. Engl. J. Med. 1993; 329; 196.
26. Givehchian M, Woerner S, Lacroix J et al. Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: no evidence for altered CD44 splicing in metstasis. Oncogene 1996; 12; 1137-1144.
27. Higashikawa K, Yokozaki H, Ue T et al. Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int. J. Cancer 1996; 66; 11-17.
28. Mayer B, Jauch K, Günthert U et al. De-novo expression of CD44 and survival in gastric cancer. Lancet 1993; 342; 1019-1022.
29. Yamaguchi A, Saito M, Goi T et al. Expression of CD44 variant exons 8-10 in gastic cancer. Jpn J. Cancer Res. 1995; 86; 1166-1171.
30. Yamaguchi A, Urano T, Goi T et al. Expression of a CD44 variant containing exons 8-10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J. Clin. Oncol. 1996; 14; 1122-1127.
31. Takahashi K, Stamenkovic I, Cutler M, Saya H, Tanabe K. CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas. Oncogene 1995; 11; 2223-2232.
32. Dämmrich J, Vollmers H, Heider K, Müller-Hermelink H. Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading. J. Mol. Med. 1995; 73; 395-401.
33. Müller W, Schneiders A, Heider K-H, Meier S, Hommel G, Gabbert H. Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J. Path. 1997; 183; 222-227.
34. Danen E, Berge P, Muijen G, Jager M, Ruiter D. Expression of CD44 and the pattern of CD44 alternative splicing in uveal melanoma. Melanoma Res. 1996; 6; 31-35.
35. Friedrichs K, Franke F, Lisboa B-W et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res. 1995; 55; 5424-5433.
36. Sinn H-P, Heider K-H, Skroch-Angel P et al. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res. Treat. 1995; 36; 307-313.
37. Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 1995; 345; 615-619.
38. Charpin C, Garcia S, Bouvier C et al. Automated and quantitative immunocytochemical assays of CD44v6 in breast carcinomas. Human Path. 1997; 28; 289-296.
39. Stevens J, Palechek P, Griebling T, Midura R, Rokhlin O, Cohen M. Expression of CD44 isoforms in human prostate tumor cell lines. Prostate 1996; 28; 153-161.
40. Rossi G, Marroni P, Paganuzzi M et al. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia 1997; 11; 134-141.
41. Gansauge F, Gansauge S, Zobywalski A et al. Differential expression of CD44 splice variants in human pancreatic adenocarcinoma and in the normal pancreas. Cancer Res. 1995; 55; 5499-5503.
42. Satoh K, Shimosegawa T, Koizumi M, Toyota T. Expression of CD44 in duct cell carcinomas and in intraductal neoplasms of the pancreas. Anticancer Res. 1997; 17; 215-220.
43. Ermak G, Jennings T, Robinson L, Ross J, Figge J. Restricted patterns of CD44 variant expression in human papillary thyroid carcinoma. Cancer Res. 1996; 56; 1037-1042.
44. Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br. J. Cancer 1995; 72; 1494-1497.
45. Wang H, DeYoung B, Swanson P, Wick M. CD44 immunoreactivity in soft-tissue sarcomas. Appl. Immunohist. 1996; 4; 184-189.
46. Gao A, Lou W, Dong J-T, Issacs J. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res. 1997; 57; 846-849.
47. Enneking WF. Staging musculoskeletal neoplasms. Skel. Radiol. 1985; 13; 183-194.
48. Trojani M, Contesso G, Coindre J et al. Soft tissue sarcomas of adults: study of pathological and prognostic variables and definition of a histological grading system. Int. J. Cancer 1984; 33; 37.
49. Mullen J, Zagars G. Synovial sarcoma outcome following conservation surgery and radiotherapy. Radio Oncol. 1994; 33; 23-30.
50. Oda Y, Hashimoto H, Tsuneyoshi M, Takeshita S. Survival in Synovial Sarcoma. Am. J. Surg. Pathol. 1993; 17; 35-44.
51. Brodsky J, Burt M, Hajdu S, Casper E, Brennan M, Tendosynovial sarcoma. Clinicopathologic features, treatment and prognosis. Cancer 1992; 70; 484-489.
52. Potter D, Kinsella T, Glatstein E et al. High-grade soft tissue sarcomas of the extremities. Cancer 1986; 58; 190-205.
53. Merzak A, Koocheckpour S, Pilkington G. CD44 mediates human glioma cell adhesion and invasion in vitro. Cancer Res. 1994; 54; 3988-3992.
54. Kogerman P, Sy M, Culp L. Oncogene-dependent expression of CD44 in Balb/c 3T3 derivatives: correlation with metastatic competence. Clin. Exp. Metastasis 1996; 14; 73-82.
55. Zöller M. CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J. Mol. Med. 1995; 73; 425-438.
56. Korabiowska M, Brinck U, Hönig J, Mora O, Bartkowski S, Schauer A. CD44: a marker of metastases of head and neck melanomas. In Vivo 1995; 9; 253-256.
57. Guarino M. Immunohistochemical distribution of basement membrane type IV collagen and laminin in synovial sarcoma. Tumori 1993; 79; 427-432.
58. Lopes J, Bjerkehagen B, Sobrinho-Simoes M, Nesland J. The ultrastructural spectrum of synovial sarcomas: a study of the epithelial type differentiation of primary tumors, recurrences, and metastases. Ultrastruc. Path. 1993; 17; 137-151.
59. Jorgensen L, Lyon H, Myhre-Jensen O, Nordentoft A, Sneppen O. Synovial sarcoma. An immunohistochemical study of the epithelial component. APMIS 1994; 102; 191-196.
60. Lopes J, Bjerkehagen B, Holm R, Bruland Ö, Sobrinho-Simões M, Nesland J. Immunohistochemical profile of synovial sarcoma with emphasis on the epithelial-type differentiation. A study of 49 primary tumours, recurrences and metastases. Path. Res. Pract. 1994; 190; 168-177.
61. Guarino M, Christensen L. Immunohistochemical analysis of extracellular matrix components in synovial sarcoma. J. Path. 1994; 172; 279-286.
62. Yu Q, Toole B. Common pattern of CD44 isoforms is expressed in morphogenetically active epithelia. Dev. Dynam. 1997; 208; 1-10.
63. Renwick P, Reeves B, Cin P et al. Two categories of synovial sarcoma defined by divergent chromosome translocation breakpoints in Xp 11.2, with implications for the histologic subclassification of synovial sarcoma. Cytogenet. Cell Genet. 1995; 70; 58-63.
64. Kawai A, Woodruff J, Healey J, Brennan M, Antonescu C, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N. Engl. J. Med. 1998; 338; 153-60.
65. Shipley J, Crew J, Birdsall S et al. Interphase fluorescence in situ hybridization and reverse transcription polymerase chain reaction as a diagnostic aid for synovial sarcoma. Am. J. Pathol. 1996; 148; 559-567.